Patents by Inventor Maria de los Ángeles Estiarte-Martinez

Maria de los Ángeles Estiarte-Martinez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLODEXTRIN DIMERS AND USES THEREOF
    Publication number: 20240043661
    Abstract: CD dimers, CD compositions, and uses thereof are disclosed herein. CD dimers, and compositions thereof, that may be useful for various purposes including the targeting of 7KC. The design and testing of CD dimers are described herein. Exemplary CD dimers include heterodimers, homodimers, or asymmetric dimer.
    Type: Application
    Filed: July 7, 2021
    Publication date: February 8, 2024
    Inventors: Matthew S. O'Connor, Maria de los Angeles Estiarte-Martinez, Amelia M. Anderson, Daniel M. Clemens, Christine A.T.M.B. Tom, Milo Malanga, Michael Kope, Keivan Sadrerafi
  • Thrombin inhibitors, formulations, and uses thereof
    Patent number: 11865110
    Abstract: Thrombin-inhibiting acylated pyrazole-pyridone compounds of formula (II) are disclosed herein, as well as pharmaceutical compositions, including tablets, that contain acylated pyrazole-pyridone compounds. These compounds are useful for the treatment and prevention of thrombin-related related diseases and disorders. Processes for making tablets containing acylated pyrazole-pyridones are also included.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: January 9, 2024
    Assignee: Verseon International Corporation
    Inventors: Kevin Michael Short, Maria de los Angeles Estiarte-Martinez, David Ben Kita, Nilantha Sudath Sirisoma
  • CYCLODEXTRIN DIMERS AND USES THEREOF
    Publication number: 20210403607
    Abstract: CD dimers, CD compositions, and uses thereof are disclosed herein.
    Type: Application
    Filed: July 7, 2021
    Publication date: December 30, 2021
    Inventors: Matthew S. O'Connor, Maria de los Angeles Estiarte-Martinez, Amelia M. Anderson, Daniel M. Clemens, Christina A.T.M.B. Tom, Milo Malanga, Michael Kope, Keivan Sadrerafi
  • THROMBIN INHIBITORS, FORMULATIONS, AND USES THEREOF
    Publication number: 20210315877
    Abstract: Thrombin-inhibiting acylated pyrazole-pyridone compounds of formula (II) are disclosed herein, as well as pharmaceutical compositions, including tablets, that contain acylated pyrazole-pyridone compounds. These compounds are useful for the treatment and prevention of thrombin-related related diseases and disorders. Processes for making tablets containing acylated pyrazole-pyridones are also included.
    Type: Application
    Filed: July 12, 2019
    Publication date: October 14, 2021
    Inventors: Kevin Michael SHORT, Maria de los Angeles ESTIARTE-MARTINEZ, David Ben KITA, Nilantha Sudath SIRISOMA
  • SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS
    Publication number: 20200109132
    Abstract: There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin and/or kallikrein, which compounds include substituted pyrazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which diseases or disorders are amenable to treatment or prevention by the inhibition of thrombin and/or kallikrein.
    Type: Application
    Filed: November 26, 2019
    Publication date: April 9, 2020
    Inventors: Kevin Michael SHORT, Maria de los Angeles ESTIARTE-MARTINEZ, David Ben KITA, Timothy Philip SHIAU
  • Substituted pyrazole compounds as serine protease inhibitors
    Patent number: 10532995
    Abstract: There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin and/or kallikrein, which compounds include substituted pyrazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which diseases or disorders are amenable to treatment or prevention by the inhibition of thrombin and/or kallikrein.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: January 14, 2020
    Assignee: VERSEON CORPORATION
    Inventors: Kevin Michael Short, Maria de los Angeles Estiarte-Martinez, David Ben Kita, Timothy Philip Shiau
  • PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS
    Publication number: 20190359586
    Abstract: There are provided inter alia pyrazolyl-substituted pyridone compounds, which exhibit biological activity, e.g., inhibitory action, against serine proteases, including thrombin and various kallikreins. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of serine proteases, including thrombin and various kallikreins.
    Type: Application
    Filed: December 7, 2018
    Publication date: November 28, 2019
    Inventors: Kevin Michael Short, David Ben Kita, Maria de los Angeles Estiarte-Martinez, Son Minh Pham
  • (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
    Patent number: 10329256
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: June 25, 2019
    Assignee: Oryzon Genomics, S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
    Patent number: 10233178
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: March 19, 2019
    Assignee: Oryzon Genomics, S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Iñigo Tirapu Fernandez De La Cuesta, Maria de los Ángeles Estiarte Martinez
  • (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
    Patent number: 10214477
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: February 26, 2019
    Assignee: Oryzon Genomics S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
    Patent number: 10189810
    Abstract: There are provided inter alia pyrazolyl-substituted pyridone compounds, which exhibit biological activity, e.g., inhibitory action, against serine proteases, including thrombin and various kallikreins. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of serine proteases, including thrombin and various kallikreins.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: January 29, 2019
    Assignee: VERSEON CORPORATION
    Inventors: Kevin Michael Short, David Ben Kita, Maria de los Angeles Estiarte-Martinez, Son Minh Pham
  • (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS
    Publication number: 20180354902
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Application
    Filed: March 5, 2018
    Publication date: December 13, 2018
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Angeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS
    Publication number: 20180237421
    Abstract: There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin and/or kallikrein, which compounds include substituted pyrazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which diseases or disorders are amenable to treatment or prevention by the inhibition of thrombin and/or kallikrein.
    Type: Application
    Filed: February 29, 2016
    Publication date: August 23, 2018
    Inventors: Kevin Michael SHORT, Maria de los Angeles ESTIARTE-MARTINEZ, David Ben KITA, Timothy Philip SHIAU
  • ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
    Publication number: 20180127406
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Application
    Filed: June 15, 2017
    Publication date: May 10, 2018
    Inventors: Alberto ORTEGA MUÑOZ, Matthew Colin Thor FYEE, Marc MARTINELL PEDEMONTE, Iñigo TIRAPU FERNANDEZ DE LA CUESTA, Maria de los Ángeles ESTIARTE MARTINEZ
  • (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
    Patent number: 9944601
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: April 17, 2018
    Assignee: ORYZON GENOMICS, S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS
    Publication number: 20180079709
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Application
    Filed: April 26, 2017
    Publication date: March 22, 2018
    Inventors: Alberto ORTEGA MUÑOZ, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS
    Publication number: 20170267656
    Abstract: There are provided inter alia pyrazolyl-substituted pyridone compounds, which exhibit biological activity, e.g., inhibitory action, against serine proteases, including thrombin and various kallikreins. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of serine proteases, including thrombin and various kallikreins.
    Type: Application
    Filed: September 17, 2015
    Publication date: September 21, 2017
    Inventors: Kevin Michael SHORT, David Ben KITA, Maria de los Angeles ESTIARTE-MARTINEZ, Son Minh PHAM
  • Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
    Patent number: 9708309
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: July 18, 2017
    Assignee: ORYZON GENOMICS, S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Iñigo Tirapu Fernandez De La Cuesta, Maria de los Ángeles Estiarte-Martinez
  • Cyclopropylamine derivatives useful as LSD1 inhibitors
    Patent number: 9676701
    Abstract: The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: June 13, 2017
    Assignee: ORYZON GENOMICS, S.A.
    Inventors: Matthew Colin Thor Fyfe, Alberto Ortega Muñoz, Julio Castro-Palomino Laria, Marc Martinell Pedemonte, Maria de los Angeles Estiarte-Martinez, Nuria Valls Vidal
  • (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
    Patent number: 9670136
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: June 6, 2017
    Assignee: ORYZON GENOMICS S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria